More than twenty-six repurposing projects have been developed during 2010-2012 giving rise to five drugs with promising experimental results, being the most advanced drug SOM0226 for the treatment of Amyloidosis TTR as a protein stabilizer and fibril disruptive drug. Several patents are in writing process or have been filed recently.
